Literature DB >> 24459191

Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination.

Peter F Wright1, Wendy Wieland-Alter, Natalia A Ilyushina, Anne G Hoen, Minetaro Arita, Austin W Boesch, Margaret E Ackerman, Harrie van der Avoort, M Steven Oberste, Mark A Pallansch, Anthony H Burton, Mohammad A Jaffar, Roland W Sutter.   

Abstract

BACKGROUND: Response to challenge with live, attenuated, oral polio vaccine (OPV) is a measure of immunity induced by prior immunization.
METHODS: Using stool samples from a study from Oman in which an initial schedule of inactivated polio vaccine (IPV) was followed by an OPV type 1 challenge, we quantitated virus shed, sequenced capsid proteins of recovered virus, and developed assays for neutralization of poliovirus and mucosal immunoglobulin A (IgA) detection.
RESULTS: Neutralizing activity correlated with detection of polio-specific IgA in stool suspensions collected 7 days after OPV type 1 challenge. Both neutralization and IgA in stool were associated with cessation of virus shedding by day 7. Rapid development of an IgA response with cessation of shedding suggests that IPV primed for the early response to challenge. Correlation of neutralization activity and IgA detection provides evidence that polio-specific IgA intestinal antibody is a determinant of mucosal shedding/transmission and that IgA functions through neutralization of virus. In contrast, neither presence nor quantity of serum or intestinal antibody induced by IPV prior to challenge correlated with cessation of shedding.
CONCLUSIONS: These assays provide an opportunity to study other immunization schedules to gain a broader understanding of the appearance and duration of a protective mucosal response to polio vaccination.

Entities:  

Keywords:  IgA; mucosal immunity; polio; vaccine

Mesh:

Substances:

Year:  2014        PMID: 24459191     DOI: 10.1093/infdis/jit671

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

Review 1.  Poliomyelitis is a current challenge: long-term sequelae and circulating vaccine-derived poliovirus.

Authors:  Jorge Quarleri
Journal:  Geroscience       Date:  2022-10-19       Impact factor: 7.581

2.  Correlates of Immunity to Influenza as Determined by Challenge of Children with Live, Attenuated Influenza Vaccine.

Authors:  Peter F Wright; Anne G Hoen; Natalia A Ilyushina; Eric P Brown; Margaret E Ackerman; Wendy Wieland-Alter; Ruth I Connor; Sinthujan Jegaskanda; Yael Rosenberg-Hasson; Brenda C Haynes; Catherine J Luke; Kanta Subbarao; John J Treanor
Journal:  Open Forum Infect Dis       Date:  2016-05-23       Impact factor: 3.835

3.  Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants.

Authors:  Peter F Wright; Ruth I Connor; Wendy F Wieland-Alter; Anne G Hoen; Austin W Boesch; Margaret E Ackerman; M Steven Oberste; Chris Gast; Elizabeth B Brickley; Edwin J Asturias; Ricardo Rüttimann; Ananda S Bandyopadhyay
Journal:  Lancet Infect Dis       Date:  2016-09-13       Impact factor: 25.071

4.  Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine.

Authors:  Elizabeth B Brickley; Carolyn B Strauch; Wendy F Wieland-Alter; Ruth I Connor; Shu Lin; Joshua A Weiner; Margaret E Ackerman; Minetaro Arita; M Steven Oberste; William C Weldon; Xavier Sáez-Llorens; Ananda S Bandyopadhyay; Peter F Wright
Journal:  J Infect Dis       Date:  2018-01-17       Impact factor: 5.226

5.  Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles.

Authors:  Eric P Brown; Karen G Dowell; Austin W Boesch; Erica Normandin; Alison E Mahan; Thach Chu; Dan H Barouch; Chris Bailey-Kellogg; Galit Alter; Margaret E Ackerman
Journal:  J Immunol Methods       Date:  2017-02-03       Impact factor: 2.303

6.  Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system.

Authors:  Jessica A White; Jeremy S Blum; Nancy A Hosken; Joshua O Marshak; Lauren Duncan; Changcheng Zhu; Elizabeth B Norton; John D Clements; David M Koelle; Dexiang Chen; William C Weldon; M Steven Oberste; Manjari Lal
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Human Circulating Antibody-Producing B Cell as a Predictive Measure of Mucosal Immunity to Poliovirus.

Authors:  Ayan Dey; Natalie A Molodecky; Harish Verma; Prashant Sharma; Jae Seung Yang; Giulietta Saletti; Mohammad Ahmad; Sunil K Bahl; Thomas F Wierzba; Ranjan K Nandy; Jagadish M Deshpande; Roland W Sutter; Cecil Czerkinsky
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

8.  Modeling the spread of polio in an IPV-vaccinated population: lessons learned from the 2013 silent outbreak in southern Israel.

Authors:  Rami Yaari; Ehud Kaliner; Itamar Grotto; Guy Katriel; Jacob Moran-Gilad; Danit Sofer; Ella Mendelson; Elizabeth Miller; Amit Huppert; E Anis; E Kopel; Y Manor; O Mor; L Shulman; R Singer; M Weil
Journal:  BMC Med       Date:  2016-06-23       Impact factor: 8.775

9.  Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules.

Authors:  Ananda S Bandyopadhyay; Edwin J Asturias; Miguel O'Ryan; M Steven Oberste; William Weldon; Ralf Clemens; Ricardo Rüttimann; John F Modlin; Chris Gast
Journal:  Vaccine       Date:  2017-11-14       Impact factor: 3.641

10.  Immune responses to oral poliovirus vaccine in HIV-exposed uninfected Zimbabwean infants.

Authors:  James A Church; Sandra Rukobo; Margaret Govha; Marya P Carmolli; Sean A Diehl; Bernard Chasekwa; Robert Ntozini; Kuda Mutasa; Jean H Humphrey; Beth D Kirkpatrick; Andrew J Prendergast
Journal:  Hum Vaccin Immunother       Date:  2017-08-31       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.